Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/18/2025

Initial Management of Unilateral Uveitis

Topical Corticosteroid Therapy

  • The American College of Rheumatology recommends initiating prednisolone acetate 1% at 1-2 drops 2-4 times daily for unilateral uveitis, due to its superior corneal penetration 1
  • The American Academy of Ophthalmology suggests that topical prednisolone acetate 1% is sufficient as initial therapy for isolated anterior uveitis 1
  • If requiring more than 1-2 drops daily of prednisolone acetate 1% beyond 3 months to maintain control, consider systemic therapy, as recommended by the American College of Rheumatology 1

Systemic Immunosuppression

  • The American Academy of Ophthalmology recommends considering immediate systemic therapy if bilateral disease is present 5
  • The European League Against Rheumatism suggests that systemic immunosuppression is generally not required for isolated anterior uveitis unless poor prognostic factors are present 3
  • Azathioprine is a first-line systemic immunosuppression option, with level IB evidence, as recommended by the American Academy of Ophthalmology 2

Treatment Failure Criteria

  • The American College of Rheumatology recommends escalating to biologic agents if inflammation persists or worsens after 3 months of appropriate first-line therapy 6
  • Monoclonal anti-TNF antibodies, such as adalimumab or infliximab, are second-line agents for refractory noninfectious uveitis, as recommended by the American College of Rheumatology 6
  • Etanercept should be avoided due to lack of efficacy for uveitis and potential to worsen inflammation, as warned by the European League Against Rheumatism 7

Critical Pitfalls to Avoid

  • The American Academy of Ophthalmology recommends never starting systemic immunosuppression without first ruling out infectious etiologies 2
  • Systemic glucocorticoids should only be used in combination with immunosuppressive agents for posterior segment involvement, as recommended by the American College of Rheumatology 5

Monitoring Requirements

  • The American Academy of Ophthalmology recommends ophthalmologic examination every 3 months minimum while on stable systemic therapy 6
  • Follow-up within 1 month is recommended after any medication change or dose adjustment, as suggested by the American College of Rheumatology 6